Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical ...

KFAR SABA, Israel, Nov. 6, 2018 /CNW/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of joint surface lesions, announced today the publication of a study demonstrating ...

(RTTNews) - Smith & Nephew plc (SNN), Wednesday encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant for the treatment of knee cartilage defects. The recent multicentre randomised ...

Surgery performed at NYU Langone Orthopedic Hospital in New York by sports medicine surgeon Eric Strauss, MD NEW YORK and KFAR SABA, Israel, Nov. 12, 2018 /CNW/ - CartiHeal, developer of Agili-C, a ...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised ...

CartiHeal Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for its Agili-C™ implant. The implant is indicated for the treatment of an ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA-approved Cartiheal implant is available commercially in Puerto Rico and the US. Credit: Smith+Nephew / GlobeNewswire.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural ...

Please provide your email address to receive an email when new articles are posted on . CartiHeal Ltd. has announced FDA premarket approval of the Agili-C implant for treatment of ICRS grade 3 or ...

Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year period. 1 Superior functional ...